ALFA Finder| Execution period | Approximately 120 days for definitive agreements |
|---|
BSE filing, NSE: SHUKRAPHAR. Summary written from the filing by ALFA Finder's alert engine.
Shukra Pharmaceuticals Ltd: key numbers
- Share price
- ₹81.51
- Market cap
- ₹3,607 Cr
- Revenue (annual)
- ₹56.73 Cr
- Net profit (annual)
- ₹22.06 Cr
- P/E (TTM)
- 81.4×Sector 48.6×
- Promoter holding
- 51.15%+0.19% QoQ
- FII holding
- 0.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shukra Pharmaceuticals Ltd
All →Shukra Pharmaceuticals Preferential Issue
Shukra Pharmaceuticals allotted 17.35 lakh preferential equity shares at Rs 35.56 to five investors. The raise totals about Rs 6.17 Crore.
- Value
- ₹6.17 Cr
Shukra Pharmaceuticals Other Announcement
Shukra Medtech confirmed no deviation in the use of funds from its preferential convertible warrant issue. The company received ₹10.46 Crore, 75% of the consideration, from allottees.
- Value
- ₹10.46 Cr
Shukra Pharmaceuticals Q2 FY27 Results: Net Profit ₹12.7 Cr, Up 429.2% YoY
Shukra Pharmaceuticals Ltd reported revenue from operations of ₹44.2 Cr (+649.2% YoY) and net profit of ₹12.7 Cr (+429.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹12.7 Cr · +429.2% YoY
Shukra Pharmaceuticals Board Meeting Date
Shukra Medtech Limited has scheduled a board meeting on November 3, 2026, to consider and approve its unaudited financial results for the quarter ended September 2026.
Shukra Pharmaceuticals Other Announcement
Shukra Medtech submitted a revised CA certificate to NSE for its name and symbol change application. The filing requests final exchange approval for the corporate rename.
Shukra Pharmaceuticals Other Announcement
Shukra Pharmaceuticals Limited has submitted the certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Other merger & restructuring announcements
All →Jubilant Ingrevia Merger & Restructuring
Jubilant Ingrevia updated on a restructuring share subscription and purchase agreement closing in two tranches. First tranche is due by November 2026, second by September 2027.
- Execution
- First tranche by November 2026; second tranche by September 2027
Alkem Laboratories Merger & Restructuring Worth ₹9.56 Cr
Alkem incorporated a Saudi Arabian joint venture subsidiary, Alkem Pharma Company LLC, on 8 November 2026. It holds 51% after subscribing SAR 38.25 lakh, about ₹9.56 Crore.
- Value
- ₹9.56 Cr
AAA Technologies Merger & Restructuring
AAA Technologies approved four wholly owned subsidiaries in Singapore, Mauritius, Dubai and India. Each entity is in IT security, cybersecurity and technology services.
Tirupati Starch & Chemicals Merger & Restructuring Worth ₹2.98 Cr
Tirupati Starch agreed to sell its Indore immovable property to Usha and Arpit Doshi for Rs 2.98 Crore. Completion is expected by 15 January 2027, subject to conditions.
- Value
- ₹2.98 Cr
- Execution
- Completion expected on or before 15 January 2027
CFF Fluid Control Merger & Restructuring
CFF Fluid Control will form a 51% joint venture with TKMS Atlas Elektronik for anti-submarine warfare in India. No deal value is disclosed.
Trom Industries Merger & Restructuring Worth ₹0.02 Cr
Trom Industries plans to incorporate Trom Energy SPV Private Limited, a solar power subsidiary, holding 98%. The initial cash subscription is Rs 1,96,000 for 19,600 shares.
- Value
- ₹0.02 Cr